New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases.
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. Blood advances Kahn, J. M., Brazauskas, R., Tecca, H. R., Bo-Subait, S., Buchbinder, D., Battiwala, M., Flowers, M. E., Savani, B. N., Phelan, R., Broglie, L., Abraham, A. A., Keating, A. K., Daly, A., Wirk, B., George, B., Alter, B. P., Ustun, C., Freytes, C. O., Beitinjaneh, A. M., Duncan, C., Copelan, E., Hildebrandt, G. C., Murthy, H. S., Lazarus, H. M., Auletta, J. J., Myers, K. C., Williams, K. M., Page, K. M., Vrooman, L. M., Norkin, M., Byrne, M., Diaz, M. A., Kamani, N., Bhatt, N. S., Rezvani, A., Farhadfar, N., Mehta, P. A., Hematti, P., Shaw, P. J., Kamble, R. T., Schears, R., Olsson, R. F., Hayashi, R. J., Gale, R. P., Mayo, S. J., Chhabra, S., Rotz, S. J., Badawy, S. M., Ganguly, S., Pavletic, S., Nishihori, T., Prestidge, T., Agrawal, V., Hogan, W. J., Inamoto, Y., Shaw, B. E., Satwani, P. 2020; 4 (9): 2084–94Abstract
We examined the risk of subsequent neoplasms (SNs) and late mortality in children and adolescents undergoing allogeneic hematopoietic cell transplantation (HCT) for nonmalignant diseases (NMDs). We included 6028 patients (median age, 6 years; interquartile range, 1-11; range, <1 to 20) from the Center for International Blood and Marrow Transplant Research (1995-2012) registry. Standardized mortality ratios (SMRs) in 2-year survivors and standardized incidence ratios (SIRs) were calculated to compare mortality and SN rates with expected rates in the general population. Median follow-up of survivors was 7.8 years. Diagnoses included severe aplastic anemia (SAA; 24%), Fanconi anemia (FA; 10%), other marrow failure (6%), hemoglobinopathy (15%), immunodeficiency (23%), and metabolic/leukodystrophy syndrome (22%). Ten-year survival was 93% (95% confidence interval [95% CI], 92% to 94%; SMR, 4.2; 95% CI, 3.7-4.8). Seventy-one patients developed SNs (1.2%). Incidence was highest in FA (5.5%), SAA (1.1%), and other marrow failure syndromes (1.7%); for other NMDs, incidence was <1%. Hematologic (27%), oropharyngeal (25%), and skin cancers (13%) were most common. Leukemia risk was highest in the first 5 years posttransplantation; oropharyngeal, skin, liver, and thyroid tumors primarily occurred after 5 years. Despite a low number of SNs, patients had an 11-fold increased SN risk (SIR, 11; 95% CI, 8.9-13.9) compared with the general population. We report excellent long-term survival and low SN incidence in an international cohort of children undergoing HCT for NMDs. The risk of SN development was highest in patients with FA and marrow failure syndromes, highlighting the need for long-term posttransplantation surveillance in this population.
View details for DOI 10.1182/bloodadvances.2019000839
View details for PubMedID 32396620